Claims for Patent: 7,507,745

Summary for Patent: 7,507,745

Title:	Pharmaceutical compositions based on fluorenecarboxylic acid esters and soluble TNF receptor fusion proteins
Abstract:	The present invention relates to novel pharmaceutical compositions based on fluorene carboxylic acid ester derived anticholinergics of formula 1 ##STR00001## and soluble TNF receptor fusion proteins, processes for preparing them and their use in the treatment of respiratory diseases.
Inventor(s):	Meade; Christopher John Montague (Maselheim, DE), Pairet; Michel (Biberach, DE), Pieper; Michael P. (Biberach, DE)
Assignee:	Boehringer Ingelheim International GmbH (Ingelheim, DE)
Application Number:	11/038,658
Patent Claims:	1. A pharmaceutical composition, comprising one or more anticholinergics of formula 1 ##STR00008## wherein A denotes a group selected from among ##STR00009## X--denotes an anion with a single negative charge which is selected from the group consisting of fluoride, chloride, bromide, iodide, sulphate, phosphate, methanesulphonate, nitrate, maleate, acetate, citrate, fumarate, tartrate, oxalate, succinate, benzoate and p-toluenesulphonate, R.sup.15 denotes hydrogen, hydroxy, methyl, ethyl, --CF.sub.3, CHF.sub.2 or fluorine; R.sup.1' and R.sup.2' which may be identical or different denote C.sub.1-C.sub.5-alkyl which may optionally be substituted by C.sub.3-C.sub.6-cycloalkyl, hydroxy or halogen, or R.sup.1' and R.sup.2' together denote a --C.sub.3-C.sub.5-alkylene-bridge; R.sup.13, R.sup.14, R.sup.13' and R.sup.14' which may be identical or different denote hydrogen, --C.sub.1-C.sub.4-alkyl, --C.sub.1-C.sub.4-alkyloxy, hydroxy, --CF.sub.3, --CHF.sub.2, CN, NO.sub.2 or halogen, or pharmacologically acceptable acid addition salts thereof, in combination with one or more soluble TNF receptor fusion proteins (2). 2. The pharmaceutical composition according to claim 1, wherein the soluble TNF receptor fusion protein 2 is etanercept or lenercept. 3. The pharmaceutical composition according to claim 2, wherein the soluble TNF receptor fusion protein 2 is etanercept. 4. The pharmaceutical composition according to claim 1, wherein the active substances 1 and 2 are present either together in a single formulation or in two separate formulations. 5. The pharmaceutical composition according to claim 1, wherein the weight ratios of the active substances 1 to 2 are in the range from 1:2000 to 1:1. 6. The pharmaceutical composition according to claim 4 wherein a single administration corresponds to a dose of the active substance combination 1 and 2 of 1 to 10000 .mu.g. 7. The pharmaceutical composition according to claim 1, which is in a form of a formulation suitable for inhalation. 8. The pharmaceutical composition according to claim 7, wherein the formulation is selected from the group consisting of inhalable powders, inhalable solutions and inhalable suspensions. 9. The pharmaceutical composition according to claim 8, wherein the inhalable powder comprises active substances 1 and 2 in admixture with suitable physiologically acceptable excipients selected from the group consisting of monosaccharides, disaccharides, oligo- and polysaccharides, polyalcohols, salts, and mixtures thereof. 10. The pharmaceutical composition according to claim 9, wherein the excipient has a maximum mass mean aerodynamic diameter of up to 250 .mu.m. 11. The pharmaceutical composition according to claim 9, wherein the inhalable powder is in a capsule. 12. The pharmaceutical composition according to claim 8, wherein the inhalable powder contains only the active substances 1 and 2 as its ingredients. 13. The pharmaceutical composition according to claim 8, wherein the inhalable solution or suspension contains water, ethanol or a mixture of ethanol and water as solvent. 14. The pharmaceutical composition according to claim 13, wherein the inhalable solution or suspension has a pH of 2-7. 15. The pharmaceutical composition according to claim 11, wherein the capsule is administered in an inhaler. 16. The pharmaceutical composition according to claim 13, wherein the inhalable solution or suspension is administered by nebulizing in a suitable inhaler. 17. The pharmaceutical composition according to claim 1, further comprising one or more pharmaceutically acceptable excipients. 18. A method of treating COPD or asthma comprising administering to a patient in need thereof the pharmaceutical composition according to claim 1.

Details for Patent 7,507,745

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Immunex Corporation	ENBREL	etanercept	For Injection	103795	11/02/1998		2024-02-20
Immunex Corporation	ENBREL	etanercept	For Injection	103795	05/27/1999		2024-02-20
Immunex Corporation	ENBREL	etanercept	Injection	103795	09/27/2004		2024-02-20
Immunex Corporation	ENBREL	etanercept	Injection	103795	02/01/2007		2024-02-20